Riluzole is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Riluzole (brand names: Rilutek, Tiglutik, Exservan) is a benzothiazole-class neuroprotective drug and the first medication approved by the United
States Food and Drug Administration (FDA) for the treatment of amyotrophic lateral sclerosis (ALS). Approved in December 1995 in the US and in 1996
by the European Medicines Agency (EMA), riluzole remains one of only two FDA-approved disease-modifying therapies for ALS, alongside
edaravone [1] [2]. The drug's primary
mechanism involves modulation of glutamatergic neurotransmission, specifically by inhibiting glutamate release and blocking voltage-gated sodium
channels on damaged neurons [3].
Riluzole was originally developed by Rhône-Poulenc (now Sanofi) and was first studied as an anticonvulsant before its neuroprotective properties were
recognized. The drug provides a modest but statistically significant survival benefit in ALS, extending median survival by approximately 2–3 months in
clinical trials, though real-world evidence suggests the benefit may be considerably larger [4]
[5].
Despite its modest efficacy, riluzole represented a landmark achievement as the first drug to demonstrate any effect on the course of a Motor Neuron Disease and remains a cornerstone of ALS treatment worldwide.
The precise mechanism of action of riluzole in ALS is not fully elucidated, but extensive preclinical and clinical evidence points to a primary role
in modulating excitotoxicity—the pathological overactivation of glutamate receptors that contributes to [neuronal death] in ALS and other
neurodegenerative conditions [3] [6].
Riluzole inhibits presynaptic glutamate release through multiple complementary mechanisms:
In addition to its presynaptic effects, riluzole has been shown to interact with several postsynaptic targets:
Beyond glutamate modulation, riluzole exerts additional neuroprotective effects:
Riluzole is well absorbed after oral administration, with a bioavailability of approximately 60% due to first-pass hepatic metabolism. Key pharmacokinetic parameters include [1]:
| Parameter | Value |
|---|---|
| Bioavailability | ~60% |
| Protein binding | 96% (mainly to albumin and lipoproteins) |
| Metabolism | Hepatic, primarily CYP1A2 |
| Half-life | ~12 hours (after repeated dosing) |
| Excretion | Renal (90%, primarily as metabolites) |
| Tmax | ~1.5 hours |
Riluzole undergoes extensive hepatic metabolism, primarily via cytochrome P450 1A2 (CYP1A2). The main metabolic pathway involves N-hydroxylation to form the primary metabolite N-hydroxyriluzole, followed by glucuronidation to form O- and N-glucuronides that are eliminated in the urine [1]. CYP1A2 inducers (e.g., smoking, omeprazole, rifampicin) can accelerate riluzole metabolism, while CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin) can increase drug levels.
The recommended dose is 50 mg taken orally twice daily (100 mg/day total), at least one hour before or two hours after meals to optimize absorption. Riluzole is available in several formulations [7]:
The first randomized controlled trial of riluzole in ALS was published in the New England Journal of Medicine in 1994. [This multicenter study
enrolled 155 patients and demonstrated that riluzole 100 mg/day significantly improved survival at 12 months compared with placebo (74% vs. 58%, p =
0.014). The survival benefit was most pronounced in patients with bulbar-onset ALS [4].
A larger confirmatory dose-ranging trial enrolled 959 patients across three doses (50, 100, and 200 mg/day) versus placebo. The study confirmed that riluzole 100 mg/day provided a statistically significant survival benefit, with a median survival prolongation of approximately 2–3 months. Higher doses (200 mg/day) showed no additional efficacy but increased toxicity [8].
Population-based studies have suggested that the real-world survival benefit of riluzole may exceed that observed in clinical trials. A 2020
systematic review of 8 real-world studies found that median survival for riluzole-treated patients was 6–19 months longer than for untreated patients
(p < 0.05), though these observational findings are subject to selection bias and confounding [5].
The most clinically significant adverse effect of riluzole is hepatotoxicity. Elevations in serum alanine aminotransferase (ALT) greater than three times the upper limit of normal occur in approximately 10–15% of patients, typically within the first three months of therapy [1]. Current guidelines recommend:
Cases of clinically apparent liver injury with jaundice are rare (estimated at fewer than 1 in 1,000 patients), and fatal hepatotoxicity has been reported only in isolated cases [1].
Other frequently reported adverse effects include [9]:
Riluzole can cause neutropenia (low neutrophil count), with cases of severe neutropenia (<500 cells/mm³) reported rarely. Complete blood count monitoring is recommended, particularly during febrile illness [9].
Rare cases of interstitial lung disease have been reported in patients receiving riluzole. Patients should be monitored for respiratory symptoms, and the drug should be discontinued if interstitial lung disease is suspected.
Given its neuroprotective properties, riluzole has been investigated in several other neurodegenerative conditions:
Riluzole's glutamate-modulating properties have attracted interest for treatment of psychiatric conditions including [11]:
Preliminary evidence suggests efficacy in treatment-resistant mood disorders, where glutamatergic dysfunction has been implicated in pathophysiology.
The study of Riluzole has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.